GSA Capital Partners LLP Lowers Stake in Medtronic PLC $MDT

GSA Capital Partners LLP lessened its holdings in Medtronic PLC (NYSE:MDT) by 87.1% during the third quarter, Holdings Channel.com reports. The firm owned 2,924 shares of the medical technology company’s stock after selling 19,708 shares during the quarter. GSA Capital Partners LLP’s holdings in Medtronic were worth $278,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Wealthcare Capital Partners LLC bought a new position in Medtronic during the 3rd quarter valued at approximately $207,000. Wealthcare Advisory Partners LLC increased its holdings in shares of Medtronic by 8.4% during the third quarter. Wealthcare Advisory Partners LLC now owns 9,861 shares of the medical technology company’s stock valued at $939,000 after acquiring an additional 767 shares in the last quarter. Bedel Financial Consulting Inc. purchased a new position in shares of Medtronic in the 3rd quarter worth about $212,000. Rothschild Investment LLC boosted its stake in Medtronic by 13.0% in the 3rd quarter. Rothschild Investment LLC now owns 18,519 shares of the medical technology company’s stock worth $1,764,000 after purchasing an additional 2,127 shares in the last quarter. Finally, Merit Financial Group LLC boosted its stake in Medtronic by 16.0% in the 3rd quarter. Merit Financial Group LLC now owns 66,159 shares of the medical technology company’s stock worth $6,301,000 after purchasing an additional 9,124 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.26% of the company’s stock.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Positive clinical readout for Altaviva tibial neuromodulation for urinary incontinence — could support future revenue and adoption in restorative/urogynecologic portfolio. Medtronic reports positive findings for Altaviva tibial neuromod
• Positive Sentiment: Analyst coverage remains constructive: consensus “Moderate Buy” and several buy/overweight ratings and raised price targets underpin the stock’s positive bias; company also maintains a steady dividend (annualized ~$2.84, ~2.9% yield). Medtronic PLC Given Average Recommendation of “Moderate Buy” by Analysts
• Neutral Sentiment: Mixed recent share performance and valuation commentary: short-term momentum is cooling (negative returns over recent weeks/months) though 1‑year TSR remains positive — investors are watching whether earnings/guidance sustain the multiple. Assessing Medtronic (MDT) Valuation After Mixed Recent Share Performance
• Neutral Sentiment: Analysis shows MDT has underperformed the S&P 500 over the past year, which may cap sentiment despite company fundamentals — useful context for relative-performance and ETF/sector flows. How Medtronic Impacted The Healthcare Sector on The S&P 500 Chart
• Negative Sentiment: Large insider sale: EVP Harry Skip Kiil sold 52,524 shares (~$5.13M at ~$97.71) and materially reduced his position — raises some investor caution though insiders may sell for personal/liquidity reasons rather than company outlook. Medtronic EVP Harry Skip Kiil Sells 52,524 Shares

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Barclays reaffirmed an “overweight” rating and issued a $118.00 target price on shares of Medtronic in a report on Wednesday, February 18th. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. CICC Research began coverage on Medtronic in a research note on Friday, January 30th. They set an “outperform” rating on the stock. The Goldman Sachs Group set a $111.00 target price on Medtronic and gave the stock a “neutral” rating in a report on Wednesday, November 19th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Medtronic in a report on Friday, November 14th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $110.84.

Medtronic Price Performance

Shares of MDT opened at $97.60 on Friday. The firm has a market cap of $125.31 billion, a PE ratio of 27.19, a P/E/G ratio of 2.44 and a beta of 0.71. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33. The company has a current ratio of 2.54, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The firm has a fifty day simple moving average of $98.93 and a two-hundred day simple moving average of $96.86.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.Medtronic’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were issued a $0.71 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).